Literature DB >> 22931992

Myocardial infarction following recombinant tissue plasminogen activator treatment for acute ischemic stroke: a dangerous complication.

Zhi-Gang Zhou1, Rui-Lan Wang, Kang-Long Yu.   

Abstract

Thrombolysis with intravenous tissue plasminogen activator (t-PA) is currently an approved therapy for patients with acute ischemic stroke. Acute myocardial infarction (AMI) immediately following t-PA treatment for stroke is a rare but serious complication. A case of acute myocardial infarction (MI) following IV t-PA infusion for acute stroke was observed. This is a 52-year-old male with a known history of hypertension and chest pain, who subsequently developed MI four hours after IV t-PA was administered for acute ischemic stroke. The disruption of intra-cardiac thrombus and subsequent embolization to the coronary arteries may be an important mechanism. In addition, spontaneous recanalization of infarct-related arteries may be associated with greater myocardial salvage and better prognosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22931992

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  3 in total

1.  Acute Ischemic Stroke Following Acute Myocardial Infarction: Adding Insult to Injury.

Authors:  Xiao-Qing Cai; Jin Wen; Ying Zhao; Ya-Li Wu; Han-Ping Zhang; Wei-Ze Zhang
Journal:  Chin Med J (Engl)       Date:  2017-05-05       Impact factor: 2.628

2.  Observation on therapeutic efficacy of rt-PA intravenous thrombolysis combined with compound anisodine injection on central retinal artery occlusion.

Authors:  Xiao-Jun Wu; Feng Gao; Xu Liu; Qing Zhao
Journal:  Exp Ther Med       Date:  2016-09-07       Impact factor: 2.447

3.  Free Fatty Acids Modulate Thrombin Mediated Fibrin Generation Resulting in Less Stable Clots.

Authors:  Anna Tanka-Salamon; Erzsébet Komorowicz; László Szabó; Kiril Tenekedjiev; Krasimir Kolev
Journal:  PLoS One       Date:  2016-12-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.